StevenIParkMD

Oncology • Concord, NC

Hematologic Oncology

Professor, Wake Forest University School of Medicine; Vice Chair for Research, Levine Cancer Institute, North Carolina

Join to view full profile

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Park's full profile

Already have an account?

Office
100 Medical Park Dr
Ste 110
Concord, NC 28025
Phone+1 704-403-1370

Summary

Lymphoma expert specializing in Hodgkin lymphoma, Non-Hodgkin lymphoma, and Chronic lymphocytic leukemia.

Google Scholar - Steven I Park, MD

Clinical Expertise

Non-Hodgkin lymphoma, Hodgkin's lymphoma, Hematologic oncology, Lymphoma

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2009
University of Washington School of MedicineFellowship, Oncology/Bmt, 2005 - 2009
University of WashingtonResidency, Internal Medicine, 2002 - 2005
University of California, Davis, School of MedicineClass of 2002
University of California, BerkeleyBA

Certifications & Licensure

NC State Medical License 2009 - 2025
WA State Medical License 2005 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma Start of enrollment: 2011 Mar 01
Completed
Phase 2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma Start of enrollment: 2017 Oct 13
Active, not recruiting
Phase 2
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma Start of enrollment: 2020 Mar 31
Active, not recruiting
Phase 1
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma Start of enrollment: 2020 Jun 11
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.
Bei Hu, Rakhee Vaidya, Ferdous Ahmed, Hamid Ehsan, Tamara K Moyo
Transplantation and Cellular Therapy. 2024-11-01
Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.
David M Foureau, Fei Guo, Nury M Steuerwald, Lawrence J Druhan, Belinda R Avalos
Experimental Hematology. 2024-01-01
1 citations
Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia.
Issam S Hamadeh, Jai N Patel, Ryan Jacobs, Hang Zeng, Jiaxian He
Clinical Cancer Research. 2023-12-01

Abstracts/Posters

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Steven I Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all